Skip to main content
Skip to footer

Akari Therapeutics

AN INNOVATIVE TARGETED ONCOLOGY COMPANY BUILT ON NEXT GENERATION ANTIBODY-DRUG CONJUGATES (ADC) AND A NOVEL DISCOVERY ENGINE

HOME
ABOUT
AREAS OF FOCUS
- Close
- PIPELINE
- POSTERS & PUBLICATIONS
INVESTOR RELATIONS
PRESS
- Close
- PRESS RELEASES
CONTACT US

Main Content

ADVANCING ANTIBODY DRUG

CONJUGATES WITH NOVEL

IMMUNO-ONCOLOGY PAYLOADS

CORPORATE PRESENTATION CORPORATE PRESENTATION GENERAL MEETING 2026 GENERAL MEETING 2026

RECENT PRESS RELEASES

Akari Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Continued Progress Toward Clinical Development of Differentiated ADC Payload Platform

November 12, 2026

Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho

November 11, 2026

Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit

October 30, 2026

Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

October 15, 2026

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

October 13, 2026

Footer

FOLLOW US

Privacy Statement

Copyright © 2026 · Akari Therapeutics · Site Designed by Polus Digital, Inc.